In this week's Pharma Pulse, PhRMA sues to block CMS's GLOBE pricing model, WFS opens a temperature-controlled cargo terminal in Lyon and Bayer commits $2.2 billion to a new Ohio manufacturing site.
Commentary|Podcasts|January 9, 2026
Pharma Pulse: Merger Fever, Lilly’s $1.2B Inflammatory Bet, and the Birth of CareTria
Author(s)Nicholas Saraceno, Senior Editor
In today’s Pharma Pulse, healthcare leaders brace for a surge in dealmaking, Eli Lilly secures a suite of oral NLRP3 inhibitors, and Knipper Health rebrands to streamline the path from order to therapy.
Advertisement
Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and let’s get into today’s headlines.
- We begin with a pulse check on industry dealmaking. According to a
new KPMG survey , 2026 is shaping up to be a year of significant consolidation. Nearly three-quarters of life sciences executives and 61% of healthcare leaders expect merger activity to ramp up this year. While healthcare systems face uncertainty over federal policies and reimbursement, the overall sentiment is bullish, with leaders looking to mergers as a primary lever for growth and operational scale after a period of relative caution. - In one of the year’s first major biopharma blockbuster deals, Eli Lilly has entered a definitive $1.2 billion agreement to acquire Ventyx Biosciences. This
all-cash transaction brings Ventyx’s promising pipeline of oral small-molecule NLRP3 inhibitors into the Lilly portfolio. These candidates target residual and chronic inflammation, which is increasingly recognized as a hidden driver in cardiometabolic health, neurodegeneration, and autoimmune diseases. - Lastly, a major evolution in the pharma services sector. Knipper Health has officially rebranded as
CareTria . The shift marks the company’s transition into a fully integrated therapy initiation platform. Following the acquisition of eBlu Solutions, Caretria is integrating digital enrollment, real-time benefit investigation, and multi-modal fulfillment into a single ecosystem.
That’s it for this episode of Pharma Pulse. For more insights on trends transforming pharmaceutical access and care delivery, visit
Thanks for listening—until next time, stay well and stay informed.
You can catch Pharma Pulse directly on
Advertisement
Related to this article
In this week's Pharma Pulse, Vicapsys merges with Stateline, Veritiv targets GLP-1 shipping, Section 232 tariffs widen and HRSA's 340B rebate pilot deadline arrives.
Cardinal Health and McKesson moved to extend CVS Health distribution deals through June 2032, retaining their largest customer pending final contracts.
Patient support data that is trusted, connected and delivered into field workflows can move access teams from reporting to faster patient intervention.
As more pharmacies dispense GLP-1s, payment processor reviews, higher fees and account closures are emerging as an overlooked point of friction in the access channel.
Eutecma's Tempaid buy pairs reusable bulk shippers with last-mile mailers as smaller, more frequent refrigerated shipments reshape demand.
As patient expectations continue to evolve, brick-and-mortar pharmacy’s path forward lies in combining trusted, face-to-face care with the efficiency and convenience patients increasingly value.
Octapharma USA's Kerem Tokel explains how product value and supply risk should shape freight security, and why complacency remains a persistent gap.
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
How Precision and Share of Answer Will Reshape Pharma Marketing
2
Supply Chain Visibility Needs Context Before AI, Says PAXAFE’s Mark Talens
3
How Lanes and Duration Shape Cold Chain Packaging Selection
4
Smart Locks, Escorts or Parcel? Matching Security to the Shipment
5